No Data
Wall Street Today: Market Decides Down is the Direction
Decoding Merck & Co's Options Activity: What's the Big Picture?
Live Stock News: Nvidia Does not run Things Around here Anymore
GTJA: Maintains SKB BIO-B "Shareholding" rating as core products enter the commercialization harvest period.
GTJA released a Research Report stating that SKB BIO-B (06990) maintains a "Shareholding" rating. The company's core products have entered a commercial harvest period, with multiple important clinical data about to be disclosed, and overseas clinical layout accelerating. Considering the uncertainty of the confirmation timeline for milestone payments from overseas partner MSD, the revenue forecasts for 2024-2026 have been adjusted to 1.732/1.67/2.666 billion yuan (previously 1.72/1.924/2.534 billion yuan). GTJA's main viewpoints are as follows: products are being continuously approved for market launch, and the first domestically produced TROP2ADC is expected to lead in clinical trials.
Wall Street Today: Market Quaking With Anticipation, and Nvidia Delivers Beat
Is Merck & Co., Inc. (MRK) the Best Retirement Stock to Buy According to Hedge Funds?
